Displaying 521 - 540 of 699
Genzyme Corporation and Ilex Oncology, Inc., In the Matter of
A consent order allowed Genzyme’s acquisition of ILEX Oncology, Inc., but requires the companies to divest certain assets in the market for solid organ transplant acute therapy drugs. Specifically, Genzyme is required to divest all contractual rights related to ILEX’s Campath®, an immunosuppressant antibody used in solid organ transplants to Schering AG.
General Electric Company, In the Matter of
General Electric was permitted to acquire InVision Technologies, Inc. with conditions that it divest InVision's YXLON x-ray nondestructive testing and inspection equipment to a Commission approved acquirer. According to the complaint issued with the consent order, the two firms are direct competitors in a highly concentrated market. The consent order protects competition in the United States market for specialized x-ray testing and inspection including standard x-ray cabinets; x-ray systems equipped with automated defect recognition software; and high-energy x-ray generators.
Cephalon, Inc., and CIMA Labs, Inc.
The consent order settled charges that Cephalon's proposed acquisition of Cima Labs, Inc. would allow Cephalon to continue its monopoly in the United States market for drugs that eliminate or reduce the spikes of severe pain that chronic cancer patients experience. The consent order required Cephalon to grant Barr Laboratories, Inc. a fully paid, irrevocable license to make and sell a generic version of Cephalon's breakthrough cancer pain drug, Actiq, in the United States.
Buckeye Partners, L.P., and Shell Oil Company, In the Matter of
The consent order settled charges that Buckeye's proposed acquisition of five refined petroleum products pipelines and 24 petroleum products terminals in the United States from Shell Oil Company would reduce competition in the market for the terminaling of gasoline, diesel fuel, and other light petroleum products in the area of Niles, Michigan. Buckeye agreed to notify the Commission before acquiring any interest in the Niles petroleum terminal for a period of ten years.
Sanofi-Synthelabo and Aventis, In the Matter of
The consent order settled antitrust concerns that Sanofi's proposed $64 billion acquisition of Aventis would create significant overlaps in several markets for pharmaceutical products while creating the world's third largest pharmaceutical company. Under terms of the consent order, Sanofi must: 1) divest its Arixtra factor Xa inhibitor to GlaxoSmithKline, plc; 2) divest its key clinical studies for the Campto® cytotoxic colorectal cancer treatment to Pfizer, Inc. and 3) divest Aventis' contractual rights to the Estorra insomnia drug either to Sepracor, Inc. or to another Commission-approved buyer.
American Air Liquide, Inc.
FTC Accepts Divestitures in $13 Billion Merger of Enterprise Products Partners and GulfTerra Energy Partners
FTC Clears Magellan's $492.4 Million Acquisition of Shell Assets
FTC Clears Buckeye Partners $517 Million Purchase of Shell Pipelines and Terminals
GenCorp Inc., In the Matter of
A consent order allowed GenCorp Inc. to acquire Atlantic Research Corporation while requiring the divestiture of Atlantic’s in-space liquid propulsion business within six months of consummating the transaction. According to the complaint issued with the consent order, the transaction as originally planned would have lessened competition in the United States in four different types of in-space propulsion engines: monopropellant thrusters; bipropellant apogee thrusters; dual mode apogee thrusters; and biopropellant attitude control thrusters.
Itron, Inc., and Schlumberger Electricity, Inc., In the Matter of
The consent order, designed to preserve competition in the market for the manufacture and sale of mobile radio frequency automatic meter reading technologies for electric utilities in the United States, permitted Itron's $255 million acquisition of Schlumberger Electricity, Inc. The consent order requires Itron to grant a royalty-free, perpetual, and irrevocable license to Hunt Technologies, Inc., creating an effective competitor in this market that allows utility companies and others to gather electric consumption data automatically and remotely from electricity meters.
RHI AG, in the Matter of
FTC/DOJ Joint Workshop on Merger Enforcement
General Electric Company, In the Matter of
A final consent order settled antitrust concerns stemming from General Electric Company’s proposed acquisition of Agfa-Gevaert N.V.’s nondestructive testing business. According to the complaint issued with the consent order, the transaction as proposed would have eliminated competition in the United States markets for portable flaw detectors, corrosion thickness gages, and precision thickness gages - equipment used to inspect the tolerance of materials without damaging them or impairing their future usefulness. The consent order requires General Electric to divest its worldwide Panametrics Ultrasonic NDT business to R/D Tech, Inc. within 20 days after the transaction is completed.
Koninklijke DSM N.V., Roche Holding AG, and Fritz Gerber, In the Matter of
The FTC charged that, as proposed, DSM's purchase of RV&FC would have a significant adverse effect on competition in the worldwide market for phytase. Phytase is an enzyme added to certain animal feed to promote the digestion of nutrients necessary for livestock production. According to the complaint, absent relief, the transaction would lead to DSM being part of alliances that supply more than 90 percent of the $150 million phytase market worldwide. A consent order permitted DSM N.V. to acquire the Vitamins and Fine Chemicals Division of Roche Holding AG but requires DSM to divest its phytase business to BASF AG.
FTC Closes Investigation of Sunoco's Proposed Acquisition of Coastal Eagle Point Oil Company
Merger Challenges Data, 1999 – 2003
Displaying 521 - 540 of 699